Change in Oncolytic Activity of Sendai Virus during Adaptation to Cell Cultures

  title={Change in Oncolytic Activity of Sendai Virus during Adaptation to Cell Cultures},
  author={Sergei S Zainutdinov and Antonina Grazhdantseva and D. V. Kochetkov and Peter M. Chumakov and S. V. Netesov and Olga V. Matveeva and Galina Kochneva},
  journal={Molecular Genetics, Microbiology and Virology},
This work is devoted to the study of the correlation between mutational variability and cytotoxic properties of the oncolytic Sendai virus when using different culture systems. We have shown that, as a result of 12 consecutive passages in the allantoic fluid of chick embryos, Sendai virus accumulates in it in high titers without changing the RNA genomic sequence and cytotoxic properties in relation to melanoma (Mel8) and human glioma cells (U87MG). However, for the drugs obtained in this system… 
3 Citations

Figures and Tables from this paper

Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy
The prospects for using paramyxovirus receptors as biomarkers for successful personalized virotherapy for certain types of cancer and a combination of expression signatures of immune and receptor genes could be used to find a set of oncolytic viruses that are more effective for specific malignancies.
Oncolytic Viruses in Tumor Therapy: The Russian Perspective
Biotechnological advances in the development of therapeutic applications of OVs in Russia are discussed, with particular emphasis on the OV-mediated treatment of glioblastoma.
The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector
This review outlines approaches for developing vaccines against the new SARS-CoV-2 coronavirus that are based on non-pathogenic viral vectors, since it can be administered intranasally and induce a mucosal immune response that strengthens the antiviral barrier in the respiratory tract and provides reliable protection against infection.


Apoptin enhances the oncolytic activity of vaccinia virus in vitro
The results suggest that the use of apoptin can be an efficient means of enhancing the natural anticancer activity of vaccinia virus.
Mechanisms of Oncolysis by Paramyxovirus Sendai
Oncolytic paramyxoviruses are powerful inducers of interferon and other cytokynes promoting antitumor activity of various cell components of the immune response, as well as cytotoxic T lymphocytes.
Oncolysis by paramyxoviruses: preclinical and clinical studies
In general, preclinical studies and phase 1–3 clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
This is the first report to show that HVJ-E alone can eradicate tumors and the mechanism through which it induces antitumor immune responses and shows promise as a novel therapeutic for cancer immunotherapy.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency
Oncolytic paramyxoviruses include some strains of Measles, Mumps, Newcastle disease, and Sendai viruses. All these viruses are well equipped for promoting highly specific and efficient malignant cell
Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production
IL-12–conjugated HVJ-E is a promising tool for the treatment of cancers, including lung metastasis by inducing local production of IFN-γ in the lungs and generating large numbers of melanoma-specific CTLs.
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation
It is reported that inactivated, replication-defective Sendai virus particles (HVJ-E) also has an antitumor effect through non-T cell immunity, and injection caused systemic activation of NK cells and enhanced their cytotoxity against tumor cells.
Paramyxovirus Fusion and Entry: Multiple Paths to a Common End
This review discusses recent advances in the understanding of paramyxovirus F protein-mediated membrane fusion, an essential process in viral infectivity and the role of the other surface glycoproteins in receptor binding and viral entry, and the implications for viral infection.
Complete Genome Sequence of the Oncolytic Sendai virus Strain Moscow
The complete genome sequence of Sendai virus Moscow strain is reported, and anecdotal evidence for the efficacy of oncolytic virotherapy exists for this strain.
Efficient eradication of hormone‐resistant human prostate cancers by inactivated Sendai virus particle
HVJ‐E effectively targets hormone‐resistant prostate cancer by inducing apoptosis in tumor cells, as well as activating anti‐tumor immunity.